Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced positive interim safety results from Cohort 1 of their first human trial for BioLexa, aimed at treating atopic dermatitis. A total of ten subjects received the treatment twice daily for 14 days, with no serious adverse events reported. CEO Robb Knie highlighted this milestone as the company prepares for Cohort 2 enrollment later in the year. BioLexa is designed to combat bacterial biofilms that complicate infections, offering a novel mechanism for treating conditions associated with these biofilms.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a Sponsored Research Agreement with Washington University to advance the development of HT-ALZ, aimed at treating symptoms associated with Alzheimer's disease. The research will be led by Dr. John Cirrito and Dr. Carla Yuede, focusing on amyloid-beta metabolism's role in Alzheimer's. Hoth's CEO emphasized the goal of developing innovative therapeutics to meet patient needs and enhance shareholder value.
Hoth Therapeutics (NASDAQ: HOTH) announced positive preclinical trial results for its investigational therapy HT-KIT, aimed at treating mast cell-derived cancers and anaphylaxis. Conducted in humanized mast cell neoplasm models, the study demonstrated that HT-KIT significantly reduces KIT expression, induces apoptosis in neoplastic human mast cells, and inhibits tumor growth. These findings indicate HT-KIT's potential as a targeted treatment for patients affected by various aggressive cancers associated with the KIT pathway. The results were shared on June 3, 2021, during a shareholder presentation.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a virtual information session on its pipeline product, HT-KIT, aimed at treating mast cell-derived cancers and anaphylaxis, set for June 3, 2021. Dr. Glenn Cruse will present positive preclinical results, indicating HT-KIT's efficacy in inducing apoptosis in neoplastic mast cells, leading to significant tumor reduction without noticeable toxicity in animal models. Hoth aims to address unmet medical needs, focusing on patient welfare and shareholder value.
On May 24, 2021, Hoth Therapeutics announced its participation as an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting, running from May 24th through July 6, 2021. The company focuses on developing treatments for rare cancers and discusses its HT-KIT and HT-001 therapeutics. HT-KIT targets cancers from aberrant KIT signaling, while HT-001 addresses skin toxicities from EGFR inhibitor therapy. CEO Robb Knie expressed excitement about contributing to oncology advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) will host a virtual information session on May 18, 2021, at 11:00 AM ET, focusing on its pipeline product, HT-005 Z-Pods™, a novel endocannabinoid treatment for Cutaneous Lupus Erythematosus (CLE). Dr. Adam Friedman will discuss the treatment's potential, efficacy data from an animal study, and the unmet medical needs it addresses. The session aims to engage shareholders and interested parties. CEO Robb Knie emphasized the company's commitment to innovating therapies for patient needs and driving shareholder value.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an expansion of its research agreement with Virginia Commonwealth University focused on developing the COVID-19 therapeutic HT-002. This decision comes after promising preclinical results from Dr. Michael Peters using live virus assays. The research will explore HT-002's effectiveness against SARS-CoV-2 variants, informed by recent molecular modeling studies. Hoth holds an exclusive license for this peptide therapeutic, which aims to provide new treatments for COVID-19.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced plans to develop its HT-KIT mRNA Frame Shifting Therapeutic targeting rare diseases affecting fewer than 200,000 people in the U.S., including various rare cancers such as aggressive systemic mastocytosis and acute myeloid leukemia. The company aims to secure Orphan Drug Designation (ODD) for HT-KIT, which offers extended market exclusivity and financial benefits during development. This strategic move aligns with Hoth's focus on improving treatment options for patients with unmet medical needs.
Hoth Therapeutics (NASDAQ: HOTH) has announced the initiation of its first human clinical trial for topical BioLexa, targeting mild to moderate atopic dermatitis (eczema). This milestone addresses a significant unmet need for enhanced therapeutic solutions for eczema patients. The clinical trial is being conducted in Australia, with updates available on Hoth's website and ClinicalTrials.gov. CEO Robb Knie expressed enthusiasm for this advancement, highlighting its potential to improve patient quality of life.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising results for its novel anti-cancer therapeutic targeting mast cell neoplasms, demonstrating significant tumor reduction and apoptosis in humanized models. The mRNA frame shifting therapy was well-tolerated with no toxicity observed. Hoth aims to accelerate clinical trial initiation based on these findings, which could represent a major advancement in treating aggressive mast cell-derived cancers. The company emphasizes its commitment to research and development for unmet medical needs.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
